Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
I-MED Pharma Partners with Quidel to Introduce I-LID ’N LASH®, I-RELIEF® and SMTube® to the U.S Market | ||
By: Nasdaq / GlobeNewswire - 17 Oct 2018 | Back to overview list |
|
MONTREAL, Oct. 17, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is pleased to announce the signing of an exclusive distribution agreement with Quidel Corporation, a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, for I-MED Pharma’s I-LID ’N LASH® product line, the I-RELIEF® HOT & COLD THERAPY EYE MASK with THERMABEADSTM and the SMTube®. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/caa51a71-d83f-4d0c-a3c3-b620eb911f37 Daniel Hofmann, President of I-MED Pharma stated, “This is the start to a very promising partnership with a company that shares our drive and commitment to improving the ocular health of patients globally. We are confident that this alliance will lead to many further collaborations in the future.” Quidel provides InflammaDry® and AdenoPlus® Eye Health diagnostic assays, which are rapid, lateral-flow based, point-of-care (POC) products for the detection of infectious and inflammatory diseases and conditions of the eye. InflammaDry is Quidel’s diagnostic test that detects elevated levels of MMP-9, a key inflammatory marker for a condition known as “Dry Eye Syndrome”. AdenoPlus is a test on market today that differentiates between a viral and bacterial infection of acute conjunctivitis (pink eye). Both products utilize innovative patented technology, are CE marked, FDA-cleared, CLIA-waived, and complement Quidel's existing rapid diagnostic testing solutions. "We are pleased to partner with I-MED Pharma in providing ocular patients and health care providers with test-and-treat solutions at the point of care," said Rick Graham, Senior Director, Business Development of Quidel Corporation. “We look forward to growing the Eye Health business in the future through further I-MED Pharma product introductions, as well as added diagnostic testing opportunities." About I-MED Pharma I-MED Pharma is proud to have been at the forefront of managing Dry Eye Syndrome as a serious disease and invests heavily into education and developing effective dry eye products. I-MED Pharma’s ocular surface disease product range includes diagnostic tools, dry eye drops, ocular hygiene, nutrition and therapeutic accessories. About Quidel For more information, please email media@imedpharma.com or visit imedpharma.com. |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |